Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is featured in a BioMedWire editorial titled “The Quest to Repair What Multiple Sclerosis Takes Away,” which examines the urgent need for new treatments for multiple sclerosis (MS), a progressive neurological disease affecting over 2.9 million people worldwide. The editorial highlights the limitations of existing MS therapies, which can slow disease progression but cannot stop it entirely or reverse damage already done.
Quantum BioPharma is developing Lucid-MS, a patented, first-in-class drug candidate designed to directly target the myelin sheath damaged by MS. The company announced that Lucid-MS is preparing to advance into Phase 2 clinical trials, pursuing a novel approach that could potentially repair myelin degradation, the underlying mechanism of MS. This represents a significant departure from current treatments that primarily manage symptoms or reduce relapse rates.
The editorial underscores the importance of this innovative approach, as MS leads to progressive disability due to demyelination and neurodegeneration. Current disease-modifying therapies (DMTs) are effective in reducing inflammatory relapses but do not facilitate remyelination or protect against long-term neurodegeneration. Lucid-MS, if successful, could offer a therapeutic breakthrough by reversing damage and restoring neurological function.
Quantum BioPharma is a biopharmaceutical company focused on building a portfolio of innovative assets for neurodegenerative, metabolic, and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is leading the research and development of Lucid-MS. The company also invented UNBUZZD, an over-the-counter product for alcohol misuse, and retains a 19.84% stake in Unbuzzd Wellness Inc., along with royalty payments.
The editorial notes that the MS treatment landscape is ripe for innovation, and Quantum BioPharma’s Lucid-MS could address a critical unmet need. For more information, the full press release is available at https://ibn.fm/WikKX. Updates on Quantum BioPharma can be found in the company’s newsroom at https://ibn.fm/QNTM.
BioMedWire, a communications platform focused on biotechnology and life sciences, produced the editorial. It is part of the Dynamic Brand Portfolio @ IBN, which provides wire solutions, editorial syndication, press release enhancement, and social media distribution. For more information, visit https://www.BioMedWire.com.
